CAJ | 학술논문

　　目的探讨他汀强化治疗对急性冠状动脉综合征（ACS）炎症状态的影响和安全性。方法ACS患者96例，诊断后第1天立即服用阿托伐他汀钙片80 mg，第2～4天80 mg/d，第5天开始40 mg/d直至出院。观察治疗前及治疗3 d后血清TC、TG、HDL-C、LDL-C、白介素-6（IL-6）、基质金属蛋白酶-9（MMP-9）和超敏C-反应蛋白（hs-CRP）及血尿素氮（BUN）、肌酐（Cr）、谷草转氨酶（AST）浓度。结果治疗后TC、HDL-C、LDL-C、Cr、BUN浓度与治疗前比较，差异无统计学意义（P＞0．05）；治疗后TG、IL-6、MMP-9、hs-CRP浓度较治疗前明显降低（P＜0．05）；治疗后AST轻度增高5例占5．2％，无严重肾功能不全、心肌炎、横纹肌溶解等不良反应。结论强化他汀方案治疗ACS能使血清炎症因子水平下降，无明显副作用。
　　목적탐토타정강화치료대급성관상동맥종합정（ACS）염증상태적영향화안전성。방법ACS환자96례，진단후제1천립즉복용아탁벌타정개편80 mg，제2～4천80 mg/d，제5천개시40 mg/d직지출원。관찰치료전급치료3 d후혈청TC、TG、HDL-C、LDL-C、백개소-6（IL-6）、기질금속단백매-9（MMP-9）화초민C-반응단백（hs-CRP）급혈뇨소담（BUN）、기항（Cr）、곡초전안매（AST）농도。결과치료후TC、HDL-C、LDL-C、Cr、BUN농도여치료전비교，차이무통계학의의（P＞0．05）；치료후TG、IL-6、MMP-9、hs-CRP농도교치료전명현강저（P＜0．05）；치료후AST경도증고5례점5．2％，무엄중신공능불전、심기염、횡문기용해등불량반응。결론강화타정방안치료ACS능사혈청염증인자수평하강，무명현부작용。
Objective To investigate the effects of intensive atorvastatin treatment on inflammatory markers in patients with acute coronary syndrome (ACS) and its safety.Methods Ninety-six consecutive patients received 80 mg of atorvastatin on the first day when the diagnosis was confirmed and maintained the dosage of 80 mg daily for the next three days,and then 40 mg daily before discharge.The serum levels of triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol ( HDL-C),low density lipoprotein cholesterol ( LDL-C),interleukin-6 (IL-6),matrix metalloproteinase 9(MMP-9),high-sensitivity C-reactive protein(hs-CRP) were measured as well as the levels of blood urea nitrogen(BUN),creatinine(Cr),glutamic-oxaloacetic transaminase(AST) before treatment and three days after treatment.Results The levels of TG,HDL-C,LDL-C,Cr and BUN after treatment showed no significant difference compared with those before treatment (P>0.05).The levels of TG,IL-6,MMP-9 and hs-CRP decreased significantly after treatment compared with those before treatment (P<0.05).After treatment,there were 5 cases of slightly increased AST which took 5.2 percent,and the adverse reactions such as severe renal dysfunction ,myocarditis and rhabdomyolysis were not observed.Conclusion Intensive atorvastatin treatment may reduce serum levels of inflammatory factors and of no obvious side effects on patients with ACS .